XNAS
RVMD
Market cap41bUSD
Oct 30, Last price
191.31USD
1D
0.55%
1Q
2.02%
IPO
575.77%
Name
Revolution Medicines Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
61.92%
Shs. 5Y
23.34%
Rev. 5Y
-10.50%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-1.13b
L+88.52%
CFO
-898m
L+61.05%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Revolution Medicines, Inc. is a biopharmaceutical company in the clinical development phase, concentrating on creating innovative, precisely targeted therapies for cancers driven by RAS pathway dysregulation. The firm's drug development portfolio features both RAS(ON) inhibitors, which are designed for potential use as single agents, in conjunction with other RAS(ON) inhibitors, or alongside RAS companion inhibitors and various therapeutic compounds. Additionally, its pipeline includes dedicated RAS companion inhibitors intended for synergistic treatment approaches. Among its RAS(ON) inhibitors currently in Phase 1 clinical trials are RMC-6236 (targeting a broad spectrum of RAS mutations), RMC-6291 (specific to G12C), and RMC-9805 (for G12D). Further compounds in preclinical or early development include RMC-5127 (for G12V), RMC-0708 (for Q61H), and RMC-8839 (for G13C), along with ongoing programs focused on G12R and other distinct molecular targets. In the realm of RAS companion inhibitors, RMC-4630 is advancing through Phase 2 clinical assessment, while RMC-5552 is undergoing Phase 1 evaluation. Revolution Medicines, Inc. was founded in 2014 and operates from its headquarters in Redwood City, California.
Key people
Chairman of the Board, President, Chief Executive Officer · since 2014
Jack Anders
Chief Financial Officer · since 2022
Steve Kelsey
President - Research and Development · since 2017
Margaret Horn
Chief Operating Officer · since 2022
Xiaolin Wang
Executive Vice President - Development · since 2023
Jeff Cislini
Senior Vice President, General Counsel, Secretary · since 2022
Wei Lin
Chief Medical Officer · since 2023
Chief Development Officer · since 2025
Elizabeth Anderson
Independent Director · since 2015
Independent Director · since 2021
Independent Director · since 2024
Independent Director · since 2023
Independent Director · since 2022
Independent Director · since 2022
Thilo Schroeder
Independent Director · since 2018
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
700 Saginaw Drive
Redwood City, CA 94063
US
Redwood City, CA 94063
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||